

ev103

Enfortumab Vedotin Trial
in Urothelial Carcinoma

Muscle invasive bladder cancer (Cohort L)

EV-103
PHASE 1b/2
CLINICAL TRIAL

NOW
ENROLLING

A photograph of a smiling couple in winter clothing. The woman is wearing a grey knit beanie and a grey scarf, and the man is wearing a white knit scarf. They are both smiling warmly at the camera. The background is a blurred outdoor setting with trees and a path.



Enfortumab Vedotin Trial
in Urothelial Carcinoma

EV-103: A Clinical Trial for the Treatment of Urothelial Cancer

Cohort L: Enfortumab vedotin (EV) alone for the treatment of muscle invasive bladder cancer (MIBC)

WHO MAY BE ELIGIBLE TO TAKE PART?	TREATMENT	MAIN MEASURE
People with urothelial cancer that is present in the bladder and can be removed by surgery	EV and surgery to remove bladder	The number of people whose cancer can be treated with study treatment and surgery

Who may qualify for this Study?

EV-103 Cohort L is for:

- People who are 18 years or older
- People with muscle invasive bladder cancer (MIBC)
- People who are not able to receive a type of chemotherapy called cisplatin
- People who can undergo surgery to remove the tumor in their bladder

This is not a complete list of criteria for participation

About the Study

Participants in this study will receive EV. This is an open-label study, which means both the study doctor and the participant will know the treatment the participant is receiving.

- Participants who take part in the study will receive EV as an infusion into a vein (also called "IV") 2 times during a 21-day cycle (on Day 1 and Day 8) before and after surgery to remove their bladder.

What is the purpose of this Study?

The purpose of this study is to find out if EV can treat the cancer before surgery and keep the cancer from returning after surgery.

To do that, this study will look at:

- The number of participants whose bladder cancer has been treated by EV by looking at the tissue from bladder cancer surgery
- How long it takes for bladder cancer to return after surgery
- How long participants live after the beginning of treatment

This is not a complete list of outcomes that will be observed in this clinical study

The use of enfortumab vedotin (EV) described here is experimental. Because of that, not all risks are known. People who are in the study may decide to stop at any time.

If you are a person recently diagnosed with muscle invasive bladder cancer, consider learning more about the EV-103, Cohort L study.

- Contact Seagen Trial Information Support 866-333-7436
- Discuss with your doctor — bring this postcard to your next visit
- Visit: <https://clinicaltrials.gov/ct2/show/NCT03288545>

Additional information:

- Patients may receive reimbursement for approved travel expenses associated with participating in the study.
- Your cancer prognosis may or may not improve by taking part in the EV-103 study.
- People who are in the study may decide to stop at any time.

